Robert Witcher1, Amy L Dzierba2, Catherine Kim3, Pamela L Smithburger3, Sandra L Kane-Gill4. 1. New York University Langone Medical Centre, New York, NY, USA. 2. New York-Presbyterian Hospital, New York, NY, USA. 3. University of Pittsburgh, School of Pharmacy, Pittsburgh, PA, USA Department of Pharmacy, University of Pittsburgh Medical Centre, Pittsburgh, PA, USA. 4. School of Pharmacy, University of Pittsburgh, 918 Salk Hall, 3501 Terrace Street, Pittsburgh, PA 15261, USA.
Abstract
BACKGROUND: Therapeutic hypothermia (TH) improves survival and neurologic function in comatose survivors of cardiac arrest. Many medications used to support TH have altered pharmacokinetics and pharmacodynamics during this treatment. It is unknown if or at what frequency the medications used during TH cause adverse drug reactions (ADRs). METHODS: A retrospective chart review was conducted for patients admitted to an intensive care unit (ICU) after cardiac arrest and treated with TH from January 2009 to June 2012 at two urban, university-affiliated, tertiary-care medical centres. Medications commonly used during TH were screened for association with significant ADRs (grade 3 or greater per Common Terminology Criteria for Adverse Events) using three published ADR detection instruments. RESULTS: A total of 229 patients were included, the majority being males with median age of 62 presenting with an out-of-hospital cardiac arrest in pulseless electrical activity or asystole. The most common comorbidities were hypertension, coronary artery disease, and diabetes mellitus. There were 670 possible ADRs and 69 probable ADRs identified. Of the 670 possible ADRs, propofol, fentanyl, and acetaminophen were the most common drugs associated with ADRs. Whereas fentanyl, insulin, and propofol were the most common drugs associated with a probable ADR. Patients were managed with TH for a median of 22 hours, with 38% of patients surviving to hospital discharge. CONCLUSIONS: Patients undergoing TH after cardiac arrest frequently experience possible adverse reactions associated with medications and the corresponding laboratory abnormalities are significant. There is a need for judicious use and close monitoring of drugs in the setting of TH until recommendations for dose adjustments are available to help prevent ADRs.
BACKGROUND: Therapeutic hypothermia (TH) improves survival and neurologic function in comatose survivors of cardiac arrest. Many medications used to support TH have altered pharmacokinetics and pharmacodynamics during this treatment. It is unknown if or at what frequency the medications used during TH cause adverse drug reactions (ADRs). METHODS: A retrospective chart review was conducted for patients admitted to an intensive care unit (ICU) after cardiac arrest and treated with TH from January 2009 to June 2012 at two urban, university-affiliated, tertiary-care medical centres. Medications commonly used during TH were screened for association with significant ADRs (grade 3 or greater per Common Terminology Criteria for Adverse Events) using three published ADR detection instruments. RESULTS: A total of 229 patients were included, the majority being males with median age of 62 presenting with an out-of-hospital cardiac arrest in pulseless electrical activity or asystole. The most common comorbidities were hypertension, coronary artery disease, and diabetes mellitus. There were 670 possible ADRs and 69 probable ADRs identified. Of the 670 possible ADRs, propofol, fentanyl, and acetaminophen were the most common drugs associated with ADRs. Whereas fentanyl, insulin, and propofol were the most common drugs associated with a probable ADR. Patients were managed with TH for a median of 22 hours, with 38% of patients surviving to hospital discharge. CONCLUSIONS:Patients undergoing TH after cardiac arrest frequently experience possible adverse reactions associated with medications and the corresponding laboratory abnormalities are significant. There is a need for judicious use and close monitoring of drugs in the setting of TH until recommendations for dose adjustments are available to help prevent ADRs.
Entities:
Keywords:
adverse drug reactions; cardiac arrest; critical care; drug-related side effects and adverse drug reactions; intensive care; pharmacovigilance; therapeutic hypothermia
Authors: Niklas Nielsen; Kjetil Sunde; Jan Hovdenes; Richard R Riker; Sten Rubertsson; Pascal Stammet; Fredrik Nilsson; Hans Friberg Journal: Crit Care Med Date: 2011-01 Impact factor: 7.598
Authors: Donald Lloyd-Jones; Robert Adams; Mercedes Carnethon; Giovanni De Simone; T Bruce Ferguson; Katherine Flegal; Earl Ford; Karen Furie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary McDermott; James Meigs; Dariush Mozaffarian; Graham Nichol; Christopher O'Donnell; Veronique Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Randall Stafford; Julia Steinberger; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan Wong; Judith Wylie-Rosett; Yuling Hong Journal: Circulation Date: 2008-12-15 Impact factor: 29.690
Authors: Timo R de Haan; Yuma A Bijleveld; Johanna H van der Lee; Floris Groenendaal; Marcel P H van den Broek; Carin M A Rademaker; Henrica L M van Straaten; Mirjam M van Weissenbruch; Jeroen R Vermeulen; Peter H Dijk; Jeroen Dudink; Monique Rijken; Arno van Heijst; Koen P Dijkman; Danilo Gavilanes; Anton H van Kaam; Martin Offringa; Ron A A Mathôt Journal: BMC Pediatr Date: 2012-05-22 Impact factor: 2.125
Authors: Nicolas Pichon; Jean Bernard Amiel; Bruno François; Anthony Dugard; Caroline Etchecopar; Philippe Vignon Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Mina Attin; Simeon Abiola; Rijul Magu; Spencer Rosero; Michael Apostolakos; Christine M Groth; Robert Block; C D Joey Lin; Orna Intrator; Deborah Hurley; Kimberly Arcoleo Journal: Resusc Plus Date: 2020-10-09